Research programme: checkpoint inhibitors - OSE ImmunotherapeuticsAlternative Names: Effi dem; OSE-172
Latest Information Update: 22 Nov 2016
At a glance
- Originator Effimune
- Developer OSE Immunotherapeutics
- Class Monoclonal antibodies
- Mechanism of Action Checkpoint kinase inhibitors; Immunomodulators; SIRPA protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer